Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
Guided Therapeutics Stock Performance
OTCMKTS GTHP opened at $0.20 on Friday. Guided Therapeutics has a 12 month low of $0.09 and a 12 month high of $0.54. The stock has a market cap of $19.31 million, a price-to-earnings ratio of -5.00 and a beta of 0.79. The company’s 50 day moving average is $0.23 and its two-hundred day moving average is $0.30.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Read More
- Five stocks we like better than Guided Therapeutics
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
- Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
- 3 Stocks to Own If Gas Prices Keep Rising
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
